Literature DB >> 28645484

Immune Check Point Inhibition in Sarcomatoid Renal Cell Carcinoma: A New Treatment Paradigm.

Ruben Raychaudhuri1, Matthew J Riese2, Kathryn Bylow1, John Burfeind1, Alexander C Mackinnon3, Parag P Tolat4, Kenneth A Iczkowski3, Deepak Kilari5.   

Abstract

Entities:  

Keywords:  PD1/PDL-1 inhibitor; Renal cell cancer; Sarcomatoid differentiation

Mesh：

Substances：

Year:  2017        PMID： 28645484     DOI： 10.1016/j.clgc.2017.05.018

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  5 in total

1.  Oral sarcomatoid squamous cell carcinoma: a retrospective study based on 14 cases.

Authors:  Jialiang Liu; Meng Xiao; Yan'an Wang
Journal:  Histol Histopathol       Date:  2019-10-23       Impact factor: 2.303

2.  Metastatic sarcomatoid renal cell carcinoma treated with immune checkpoint inhibitors.

Authors:  Ahmad Hanif; Manu Pandey; Sumera Khan; Kristopher Attwood; Saby George
Journal:  Oncoimmunology       Date:  2019-04-25       Impact factor: 8.110

3.  Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib.

Authors:  Dylan J Martini; Meredith R Kline; Yuan Liu; Julie M Shabto; Bradley C Carthon; Greta Anne Russler; Lauren Yantorni; Emilie Elise Hitron; Sarah Caulfield; Jamie M Goldman; Wayne B Harris; Omer Kucuk; Viraj A Master; Mehmet Asim Bilen
Journal:  Cancer Treat Res Commun       Date:  2021-05-09

4.  Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis.

Authors:  Leah K Shaw; Andrew J Wiele; Kanishka Sircar; Christopher G Wood; Pavlos Msaouel
Journal:  Cancer Treat Res Commun       Date:  2021-03-10

Review 5.  Clear cell renal cell carcinoma ontogeny and mechanisms of lethality.

Authors:  Eric Jonasch; Cheryl Lyn Walker; W Kimryn Rathmell
Journal:  Nat Rev Nephrol       Date:  2020-11-03       Impact factor: 28.314
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.